Skip to main content

Table 2 Bacteriological Examinations

From: Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study

Characteristic Patients
All LC CRC Other
(n = 30) (n = 15) (n = 10) (n = 5)
Sputum smear, n (%)
 Negative 10 (33.3) 5 (33.3) 3 (30.0) 2 (40.0)
 Positive 20 (66.7) 10 (66.7) 7 (70.0) 3 (60.0)
PCR/LAMP, n (%)
 Negative 1 (3.3) 1 (6.7) 0 (0.0) 0 (0.0)
 Positive 15 (50.0) 10 (66.7) 3 (30.0) 2 (40.0)
 Unknown 14 (46.7) 4 (26.7) 7 (70.0) 3 (60.0)
Culture, n (%)
 Negative 5 (16.7) 3 (20.0) 2 (20.0) 0 (0.0)
 Positive 25 (83.3) 12 (80.0) 8 (80.0) 5 (100.0)
Sensitivity to anti-MTB agents, n (%)
 Sensitive 22 (88.0) 12 (100.0) 6 (75.0) 4 (80.0)
 Resistant 2 (8.0)a 0 (0.0) 2 (25.0) 0 (0.0)
 Unknown 1 (4.0)b 0 (0.0) 0 (0.0) 1 (20.0)b
Time until the result of Bacteriological Examination come out
  Overall Ogawa-Kudoh MGIT
Time to MTB-positive culture (days), mean ± SD, n 20.9 ± 12.4
(n=23c)
37.6 ± 8.4
(n = 5)
16.2 ± 8.7*
(n = 18)
Time to sensitivity testing (days), mean ± SD, n 12.6 ± 3.5
(n=22d)
  
  1. Abbreviations CRC colorectal cancer, LAMP loop-mediated isothermal amplification, LC lung cancer, MGIT Mycobacteria Growth Inhibitor Tube, MTB = Mycobacterium tuberculosis, PCR polymerase chain reaction, NTM Nontuberculous Mycobacteriosis
  2. *P < 0.0005
  3. aOne MTB strain was resistant to isoniazid and streptomycin, another was isoniazid and pyrazinamide
  4. bOne specimen with MTB-positive cultures and concomitant NTM was not used for sensitivity testing
  5. cIn two specimens, measure of the time to MTB-positive cultures were not possible because the culture specimens were obtained in other institutes
  6. dTwenty-two cultures except one which was concomitant NTM and two which was obtained in other institute